Gastric and intestinal ulcers result from disruption of the mucosal barrier by H. pylori, NSAIDs, stress, or excessive acid — exposing underlying tissue to corrosive gastric contents. Healing requires mucosal cell regeneration, angiogenesis to restore blood supply to the ulcer base, reduction of inflammatory infiltrate, and restoration of the protective mucus layer. BPC-157 was originally discovered in gastric juice, making GI ulcer healing its most foundational application.
1. BPC-157 — Primary Ulcer Healing Agent
BPC-157 was isolated from human gastric juice and named “Body Protection Compound” specifically for its ulcer-healing properties. It dramatically accelerates gastric and intestinal ulcer healing by promoting angiogenesis at the ulcer base, stimulating mucosal cell proliferation, reducing inflammatory infiltrate, and upregulating growth factor receptor expression on healing cells. Multiple animal studies show near-complete ulcer healing within days of BPC-157 administration.
Dosing Protocol: 500 mcg oral BPC-157 (arginate form) twice daily — once before meals in the morning and once before bed. Oral administration maximizes local gastric/intestinal exposure. Cycle: 4–8 weeks for active ulcers.
2. KPV — Mucosal Anti-Inflammatory
Ulcer healing is impaired by ongoing mucosal inflammation. KPV reduces the pro-inflammatory cytokines (TNF-α, IL-6, IL-8) that prevent ulcer margins from re-epithelializing, inhibits the NF-κB signaling that perpetuates mucosal inflammation, and has demonstrated direct protection of intestinal epithelial cells from inflammatory damage.
Dosing Protocol: 200–500 mcg oral daily (capsule for intestinal delivery). Can be combined with oral BPC-157 for synergistic mucosal healing. Cycle: 4–6 weeks.
3. VIP — Protective Secretion / Motility
VIP is a key endogenous mediator of gastric mucosal protection — stimulating protective bicarbonate and mucus secretion, normalizing gastric motility to reduce ulcer irritation, and providing direct anti-inflammatory effects on mucosal immune cells. VIP deficiency impairs the protective response of gastric mucosa to injury.
Dosing Protocol: 25–50 mcg SubQ daily. Oral/enteral VIP delivery under investigation. Cycle: 4 weeks.
4. Thymosin Alpha-1 — Immune-Mediated Ulcer Control
In H. pylori-associated and stress ulcers, dysregulated mucosal immune responses perpetuate ulcer chronicity. Thymosin Alpha-1 normalizes mucosal immune function — reducing pathological inflammatory responses that prevent healing while maintaining the immune competence needed to combat H. pylori and other ulcerogenic factors.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks, then weekly. Cycle: 8 weeks for ulcer indication.
BPC-157 is the cornerstone — directly healing the ulcer through angiogenesis and mucosal cell regeneration. KPV suppresses the mucosal inflammation that prevents re-epithelialization of the ulcer margins. VIP restores the protective secretions and motility patterns that defend healed mucosa from re-injury. Thymosin Alpha-1 corrects the immune dysregulation that allows ulcers to persist in the face of conventional therapy.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).